CO6430464A2 - Derivados de amida como ligandos del receptor y5 del neuropéptido - Google Patents
Derivados de amida como ligandos del receptor y5 del neuropéptidoInfo
- Publication number
- CO6430464A2 CO6430464A2 CO11121403A CO11121403A CO6430464A2 CO 6430464 A2 CO6430464 A2 CO 6430464A2 CO 11121403 A CO11121403 A CO 11121403A CO 11121403 A CO11121403 A CO 11121403A CO 6430464 A2 CO6430464 A2 CO 6430464A2
- Authority
- CO
- Colombia
- Prior art keywords
- neuropeptide
- ligands
- amida
- derivatives
- receiver
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 206010012289 Dementia Diseases 0.000 abstract 1
- 101710151321 Melanostatin Proteins 0.000 abstract 1
- 102400000064 Neuropeptide Y Human genes 0.000 abstract 1
- 102100029549 Neuropeptide Y receptor type 5 Human genes 0.000 abstract 1
- 101710198055 Neuropeptide Y receptor type 5 Proteins 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000036651 mood Effects 0.000 abstract 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000035882 stress Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto de Fórmula I:La presente invención se refiere a compuestos novedosos los cuales son ligandos en el receptor Y5 del neuropéptido Y. Los aspectos separados de la invención se refieren a composiciones farmacéuticas que comprenden dichos compuestos y usos de los compuestos para tratar trastornos relacionados con el estado de ánimo, el estrés, la cognición y la demencia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16180209P | 2009-03-20 | 2009-03-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6430464A2 true CO6430464A2 (es) | 2012-04-30 |
Family
ID=42740244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO11121403A CO6430464A2 (es) | 2009-03-20 | 2011-09-19 | Derivados de amida como ligandos del receptor y5 del neuropéptido |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20120101078A1 (es) |
| EP (1) | EP2408767B1 (es) |
| JP (1) | JP2012521350A (es) |
| KR (1) | KR20110136818A (es) |
| CN (1) | CN102356079A (es) |
| AR (1) | AR075898A1 (es) |
| AU (1) | AU2010226553B2 (es) |
| BR (1) | BRPI1014526A2 (es) |
| CA (1) | CA2756003A1 (es) |
| CL (1) | CL2011002319A1 (es) |
| CO (1) | CO6430464A2 (es) |
| EA (1) | EA201171149A1 (es) |
| IL (1) | IL215226A0 (es) |
| MX (1) | MX2011009886A (es) |
| NZ (1) | NZ595265A (es) |
| SG (1) | SG174472A1 (es) |
| TW (1) | TW201103907A (es) |
| WO (1) | WO2010108052A2 (es) |
| ZA (1) | ZA201106812B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9968574B2 (en) | 2009-05-15 | 2018-05-15 | The University Of Kentucky Research Foundation | Treatment of MCI and Alzheimer's disease |
| CN102984938A (zh) * | 2010-05-13 | 2013-03-20 | 肯塔基大学研究基金会 | 轻度认知障碍(mci)和阿尔茨海默氏症的治疗方法 |
| HU231206B1 (hu) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepinek |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6399631B1 (en) * | 1999-07-23 | 2002-06-04 | Pfizer Inc. | Carbazole neuropeptide Y5 antagonists |
| DK1202986T3 (da) * | 1999-07-28 | 2006-02-20 | Ortho Mcneil Pharm Inc | Amin- og amidderivater som ligander for neuropeptid Y-Y5-receptoren, der er nyttige ved behandlingen af obesitet og andre lidelser |
| WO2004089919A1 (ja) * | 2003-04-02 | 2004-10-21 | Banyu Pharmaceutical Co., Ltd. | シクロヘキサンカルボキサミド誘導体 |
| JP2006298909A (ja) * | 2005-03-25 | 2006-11-02 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
-
2010
- 2010-03-18 TW TW099107952A patent/TW201103907A/zh unknown
- 2010-03-19 BR BRPI1014526A patent/BRPI1014526A2/pt not_active IP Right Cessation
- 2010-03-19 WO PCT/US2010/027892 patent/WO2010108052A2/en not_active Ceased
- 2010-03-19 EA EA201171149A patent/EA201171149A1/ru unknown
- 2010-03-19 JP JP2012500981A patent/JP2012521350A/ja active Pending
- 2010-03-19 MX MX2011009886A patent/MX2011009886A/es active IP Right Grant
- 2010-03-19 AU AU2010226553A patent/AU2010226553B2/en not_active Ceased
- 2010-03-19 EP EP10754142.7A patent/EP2408767B1/en active Active
- 2010-03-19 CA CA2756003A patent/CA2756003A1/en not_active Abandoned
- 2010-03-19 AR ARP100100893A patent/AR075898A1/es not_active Application Discontinuation
- 2010-03-19 US US13/256,981 patent/US20120101078A1/en not_active Abandoned
- 2010-03-19 SG SG2011067741A patent/SG174472A1/en unknown
- 2010-03-19 KR KR1020117021983A patent/KR20110136818A/ko not_active Withdrawn
- 2010-03-19 CN CN2010800135437A patent/CN102356079A/zh active Pending
- 2010-03-19 NZ NZ595265A patent/NZ595265A/xx not_active IP Right Cessation
-
2011
- 2011-09-19 IL IL215226A patent/IL215226A0/en unknown
- 2011-09-19 CO CO11121403A patent/CO6430464A2/es not_active Application Discontinuation
- 2011-09-19 ZA ZA2011/06812A patent/ZA201106812B/en unknown
- 2011-09-20 CL CL2011002319A patent/CL2011002319A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR075898A1 (es) | 2011-05-04 |
| IL215226A0 (en) | 2011-12-29 |
| CA2756003A1 (en) | 2010-09-23 |
| WO2010108052A3 (en) | 2011-02-24 |
| EP2408767A4 (en) | 2012-08-22 |
| EA201171149A1 (ru) | 2012-03-30 |
| US20120101078A1 (en) | 2012-04-26 |
| NZ595265A (en) | 2013-02-22 |
| BRPI1014526A2 (pt) | 2016-04-05 |
| ZA201106812B (en) | 2012-11-28 |
| CL2011002319A1 (es) | 2012-08-31 |
| EP2408767B1 (en) | 2013-07-10 |
| TW201103907A (en) | 2011-02-01 |
| WO2010108052A2 (en) | 2010-09-23 |
| JP2012521350A (ja) | 2012-09-13 |
| AU2010226553B2 (en) | 2012-05-31 |
| AU2010226553A1 (en) | 2011-10-13 |
| MX2011009886A (es) | 2011-09-30 |
| EP2408767A2 (en) | 2012-01-25 |
| KR20110136818A (ko) | 2011-12-21 |
| SG174472A1 (en) | 2011-10-28 |
| CN102356079A (zh) | 2012-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22091792A (es) | Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroplastos | |
| MX2019003738A (es) | Compuestos antivirales. | |
| CO6480975A2 (es) | Mimetico de smac | |
| CO6341558A2 (es) | Antagonistas del recepptor de nmda para el tratamiento de trastornos neuropsiquiatricos | |
| ECSP11010804A (es) | Compuestos orgánicos | |
| CO7310531A2 (es) | 4-metil-2,3,8,9,9b-pentaaza-ciclopenta [a] naftalenos | |
| DOP2017000013A (es) | Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas | |
| GT201500138A (es) | Novedososo derivados de bencimidazol como antagonistas de ep4 | |
| CR20140071A (es) | Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa | |
| GT201200230A (es) | Inhibidores del virus de la hepatitis c | |
| UY33735A (es) | Compuestos antivirales | |
| CR20200276A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059) | |
| CR20130102A (es) | Imidazopiridazinas sustituidas | |
| UY32574A (es) | Antagonistas del receptor cxcr3 | |
| CR20150117A (es) | Derivados c17-alcandilo y alquendilo del ácido oleanólico y sus métodos de uso | |
| UY32426A (es) | Derivados bicilicos para uso en el tratamiento de enfermedades relacionadas al receptor de androgeno | |
| UY33557A (es) | Inhibidores de oxadiazol de la produccion de leucotrieno | |
| UY32077A (es) | Inhibidores de quinasa tipo polo | |
| MX340816B (es) | Compuestos que inhiben el glioblastoma y su uso. | |
| CO6341625A2 (es) | Derivados de indol como agentes anticáncer | |
| UY32744A (es) | Derivados de 2-carboxamida-7-piperazinil-benzofurano 774 | |
| CO6321288A2 (es) | Sales de compuestos inhibidores de vih | |
| CO6321246A2 (es) | Compuestos novedosos activos como antagonistas de receptor muscarinico | |
| CO6430464A2 (es) | Derivados de amida como ligandos del receptor y5 del neuropéptido | |
| UY31646A1 (es) | Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabólico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |